Log Out

Gilead Sciences (NASDAQ:GILD) Given New $112.00 Price Target at Piper Sandler

Financial News Live · Feb 7, 2023 03:04

Gilead Sciences (NASDAQ:GILD – Get Rating) had its price target raised by Piper Sandler from $111.00 to $112.00 in a research note issued to investors on Friday, The Fly reports. The brokerage currently has an overweight rating on the biopharmaceutical company's stock.

GILD has been the topic of a number of other research reports. Mizuho began coverage on shares of Gilead Sciences in a research note on Wednesday, December 21st. They issued a buy rating and a $88.00 price target on the stock. Royal Bank of Canada lowered shares of Gilead Sciences from an outperform rating to a sector perform rating and set a $87.00 price target on the stock. in a research note on Tuesday, January 3rd. Barclays upped their price target on shares of Gilead Sciences from $76.00 to $84.00 and gave the company an equal weight rating in a research note on Wednesday, January 18th. Morgan Stanley decreased their price target on shares of Gilead Sciences from $81.00 to $80.00 and set an equal weight rating on the stock in a research note on Tuesday, January 24th. Finally, Jefferies Financial Group upped their price target on shares of Gilead Sciences from $78.00 to $86.00 and gave the company a buy rating in a research note on Friday, October 28th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of $88.55.

Get Gilead Sciences alerts:

Gilead Sciences Stock Up 2.2 %

Shares of GILD stock opened at $86.36 on Friday. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.10 and a current ratio of 1.36. The firm's 50-day moving average is $85.78 and its 200-day moving average is $74.61. The stock has a market cap of $108.32 billion, a price-to-earnings ratio of 23.66, a PEG ratio of 0.79 and a beta of 0.39. Gilead Sciences has a 52-week low of $57.17 and a 52-week high of $89.74.

Gilead Sciences (NASDAQ:GILD – Get Rating) last issued its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.17. The company had revenue of $7.39 billion for the quarter, compared to analysts' expectations of $6.63 billion. Gilead Sciences had a net margin of 16.83% and a return on equity of 44.46%. Gilead Sciences's quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.69 EPS. Sell-side analysts predict that Gilead Sciences will post 6.96 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 30th. Stockholders of record on Wednesday, March 15th will be issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.47%. The ex-dividend date is Tuesday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.73. Gilead Sciences's dividend payout ratio is 80.00%.

Insider Transactions at Gilead Sciences

In other news, CAO Diane E. Wilfong sold 6,416 shares of the company's stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $83.50, for a total transaction of $535,736.00. Following the completion of the sale, the chief accounting officer now owns 28,333 shares of the company's stock, valued at approximately $2,365,805.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Institutional Trading of Gilead Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Jacobs & Co. CA lifted its stake in Gilead Sciences by 0.5% in the 4th quarter. Jacobs & Co. CA now owns 26,986 shares of the biopharmaceutical company's stock valued at $2,316,000 after purchasing an additional 127 shares during the last quarter. Capital Advisors Ltd. LLC lifted its stake in Gilead Sciences by 29.4% in the 3rd quarter. Capital Advisors Ltd. LLC now owns 607 shares of the biopharmaceutical company's stock valued at $37,000 after purchasing an additional 138 shares during the last quarter. Retirement Planning Co of New England Inc. lifted its stake in Gilead Sciences by 1.3% in the 4th quarter. Retirement Planning Co of New England Inc. now owns 10,943 shares of the biopharmaceutical company's stock valued at $939,000 after purchasing an additional 140 shares during the last quarter. Mastrapasqua Asset Management Inc. lifted its stake in Gilead Sciences by 4.5% in the 3rd quarter. Mastrapasqua Asset Management Inc. now owns 3,494 shares of the biopharmaceutical company's stock valued at $216,000 after purchasing an additional 150 shares during the last quarter. Finally, GHP Investment Advisors Inc. lifted its stake in Gilead Sciences by 1.7% in the 3rd quarter. GHP Investment Advisors Inc. now owns 8,951 shares of the biopharmaceutical company's stock valued at $552,000 after purchasing an additional 153 shares during the last quarter. Institutional investors own 78.72% of the company's stock.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.